Lymphoma
Lymphomas are cancers that strike immune cells within the lymphatic system, which is a key part of the immune system. Lymphomas are broadly classified as either Hodgkin or non-Hodgkin lymphoma. Some lymphomas are highly curable; others tend to relapse and are considered incurable with standard treatments such as chemotherapy and radiation. However, some of these lymphomas may be slow-growing and respond to various treatments over many years.
Fred Hutch researchers pioneered bone marrow transplantation, one of the most significant advances in treating lymphoma, leukemia and other blood cancers. We continue to improve bone marrow and blood stem cell transplantation for lymphoma, making these therapies safer and more effective.
Informed by our studies of basic biology, our scientists are also developing new lymphoma-targeting drugs and new tests to help guide treatment. We also carry out long-term studies to understand how survivors fare years after treatment and develop new ways to improve their health.
ON THIS PAGE
Researchers and Patient Treatments | Clinical Trials | Lymphoma Reseach
Our Lymphoma Research at Fred Hutch
Our interdisciplinary scientists and clinicians work together to prevent, diagnose and treat lymphoma as well as other cancers and diseases.
Patient Treatment & Care
At Fred Hutch, our interdisciplinary teams work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Our aim is to provide patients access to advanced treatment options while getting the best cancer care.
Selected Lymphoma Clinical Trials
Clinical research is an essential part of the scientific process that leads to new treatments and better care. Clinical trials can also be a way for patients to get early access to cutting-edge new therapies. Our clinical research teams are running clinical studies on various kinds of lymphoma.
Hodgkin Lymphoma
Hodgkin lymphoma occurs in white blood cells called lymphocytes, usually B cells. The disease is characterized by the presence of Reed-Sternberg cells, which are lymphocytes that became abnormal.
Non-Hodgkin Lymphoma
Non-Hodgkin lymphomas are a group of cancers affecting immune cells called lymphocytes, most commonly B cells but sometimes T cells. More than 40 types of non-Hodgkin lymphoma exist. The most common types are diffuse large B cell lymphoma and follicular lymphoma. Some non-Hodgkin lymphomas are caused by infections from viruses, including HIV, hepatitis C, and Epstein-Barr.
Lymphoma Research
Our lymphoma research takes place both in the clinic and in the laboratory, where we study the biology of lymphoma cells and develop potential new drugs and immunotherapies. It brings together investigators based at the Fred Hutch, the University of Washington and Seattle Cancer Care Alliance, where our world-renowned clinical researchers are developing new methods for treating and caring for lymphoma patients. Our research includes tracking survivors’ quality of life after treatment, sometimes for decades.
Survivorship and Treatment Complications
Lymphoma patients can experience numerous medical, emotional and psychosocial side effects during and after treatment. Our scientists are developing supportive care for lymphoma patients to protect them from treatment complications and improve their quality of life. They also study the long-term and late effects of lymphoma treatment to improve the quality of life for survivors, even years after treatment.
In particular, our scientists are world experts in the complications of blood stem-cell transplantation, including infections and graft-vs.-host disease. Our researchers are developing better methods to prevent and treat these complications.
Immmunotherapies
Fred Hutch researchers are contributing landmark discoveries about how to engineer immune cells called T cells to target lymphoma. Our scientists are also developing new lymphoma drugs based on antibodies, disease-targeting immune proteins. For example, we are innovators in radioimmunotherapy, in which antibodies ferry powerful radioactive isotopes straight to lymphoma cells. We are also leaders in the development of novel oral low-toxicity regimens for the treatment of lymphoma as well as immunotherapies that do not require T-cell engineering.
Targeted Drug Therapies
We are using our knowledge of the biology of lymphoma cells to devise new ways to disrupt their ability to grow and spread. The goal of targeted drug therapies is to maximize the lymphoma-killing effect while minimizing harm to healthy tissues.
Global Oncology
Burkitt lymphoma is the most common pediatric cancer in equatorial Africa. Through our Global Oncology program, we’re developing news ways to diagnose, predict, prevent and treat lymphoma and other cancers worldwide.